Organization
Hansoh BioMedical R&D Company
17 clinical trials
Clinical trial
A Phase 2, Open-label, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors (ARTEMIS-005)Status: Recruiting, Estimated PCD: 2026-07-31
Clinical trial
ARTEMIS-006: A Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Administration of HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-12
Clinical trial
ARTEMIS-003: A Phase 2, Open-label, Multi-center Study to Evaluate Efficacy, Safety, and Pharmacokinetics, of Intravenous Administration of HS-20093 in Metastasis Castration Resistant Prostate Cancer Patients Who Have Progressed Following at Least One Prior TherapyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
ARTEMIS-007: A Phase 2 Study to Evaluate Efficacy and Safety of HS-20093 in Patients With Extensive Stage Small Cell Lung CancerStatus: Withdrawn, Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HS-10384 in Chinese Postmenopausal WomenStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic ArthritisStatus: Not yet recruiting, Estimated PCD: 2026-04-28
Clinical trial
ARTEMIS-101: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
An Open-label Single-arm Clinical Study to Assess the Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD)Status: Not yet recruiting, Estimated PCD: 2024-12-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of HS-10384 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)Status: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20089 Combination Treatment in Subjects With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2026-04-08
Clinical trial
A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial CancerStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20117 in Participants With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy SubjectsStatus: Recruiting, Estimated PCD: 2024-02-16
Clinical trial
Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic and the Therapeutic Potential of HS-20105 for Injection in Patients With Advanced Solid Tumors.Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01